3 Stocks That Could See Trading Interest: Vivos Therapeutics (VVOS), Cardiol Therapeutics (CRDL), Dare Bioscience (DARE)

Healthcare and biotechnology stocks continue to attract investor attention as companies advance clinical programs, pursue regulatory milestones, and work toward commercial expansion. While market fluctuations remain common across the sector, developments related to product pipelines, financial performance, and strategic initiatives often play a significant role in shaping investor sentiment and long-term growth expectations.

Vivos Therapeutics Inc (VVOS)

Vivos Therapeutics Inc (NASDAQ: VVOS) flaunted a slowness of -0.99% at $0.68, as the Stock market unbolted on June 02, 2026. During the day, the stock rose to $0.73 and sunk to $0.65. Taking a more long-term approach, VVOS posted a 52-week range of $0.55-$7.95.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 39.15%. Meanwhile, its Annual Earning per share during the time was 39.15%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.10%. This publicly-traded company’s shares outstanding now amounts to $13.49 million, simultaneously with a float of $10.14 million. The organization now has a market capitalization sitting at $9.42 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to broaden its cardiovascular pipeline by pursuing therapies for inflammatory heart diseases that currently have limited targeted treatment options. This diversification strategy is important because it allows the company to build value beyond a single clinical program while leveraging its expertise in cardiovascular inflammation.

Market Momentum

As of June 2, 2026, CRDL closed at $1.15, down 5.74%, with trading volume of 409,173 shares versus an average volume of 677,258 shares. The company currently carries a market capitalization of $132.563M and a beta of 0.43, reflecting relatively controlled volatility compared with many development-stage biotechnology companies. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.29 suggests substantial upside potential if the company successfully executes its clinical strategy.

ARCHER and Acute Myocarditis

Beyond recurrent pericarditis, Cardiol has generated encouraging data through its Phase II ARCHER trial evaluating CardiolRx™ in acute myocarditis. This disease involves inflammation of the heart muscle and can result in impaired cardiac function, arrhythmias, and long-term cardiovascular complications. Clinical findings demonstrated favorable effects on markers of cardiac inflammation and structural measures associated with heart health, supporting continued interest in the program.

Broadening the Clinical Opportunity

Success in myocarditis could significantly expand Cardiol’s addressable market while validating the broader applicability of its anti-inflammatory platform. Importantly, positive results across multiple cardiovascular conditions strengthen the scientific hypothesis that targeting inflammation may provide meaningful therapeutic benefits beyond a single indication. This platform potential is often viewed favorably by long-term investors seeking multiple pathways to value creation.

Outlook

While MAVERIC remains the company’s lead value driver, the ARCHER program demonstrates that Cardiol’s opportunity extends beyond recurrent pericarditis. Additional progress in myocarditis could enhance the company’s growth profile, diversify development risk, and create future opportunities across a wider range of inflammatory cardiovascular diseases.

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (NASDAQ: DARE) started the day on June 02, 2026, with a price decrease of -2.28% at $2.14. During the day, the stock rose to $2.22 and sunk to $2.13. Taking a more long-term approach, DARE posted a 52-week range of $1.27-$9.19.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 35.73%. Meanwhile, its Annual Earning per share during the time was 35.73%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 21.11%. This publicly-traded company’s shares outstanding now amounts to $14.56 million, simultaneously with a float of $13.73 million. The organization now has a market capitalization of $32.06 million.